Search

Displaying results 1261 - 1270 of 10000 in total
  1. Drug

    Pegcetacoplan

    go.drugbank.com/drugs/DB16694
    ApprovedInvestigational

    [A235000] Patients given eculizumab experienced less hemolysis caused by the membrane attack complex, but were still somewhat susceptible to hemolysis caused by C3b opsonization. … [A235000] Pegcetacoplan for subcutaneous use was granted FDA approval on 14 May 2021.

  2. Drug

    Moxisylyte

    go.drugbank.com/drugs/DB09205
    Approved

    [T45] According to the WHO, moxisylyte is approved since 1987[T91] and in the same year, it acquired the denomination of orphan product by the FDA. … [L1172] This drug was developed by the Japanese company Fujirebio and also by the American company Iolab in the late 80s.

  3. Target

    Sigma non-opioid intracellular receptor 1

    go.drugbank.com/bio_entities/BE0000156
    TargetHumans

    Functions in lipid transport from the endoplasmic reticulum and is involved in a wide array of cellular functions probably through regulation of the biogenesis of lipid microdomains at the plasma membrane. Involved in the regulation of d...

    Polypeptides: Sigma non-opioid intracellular receptor 1
  4. Target

    Ecto-NOX disulfide-thiol exchanger 2

    go.drugbank.com/bio_entities/BE0002434
    TargetHumans

    May be involved in cell growth. Probably acts as a terminal oxidase of plasma electron transport from cytosolic NAD(P)H via hydroquinones to acceptors at the cell surface. Hydroquinone oxidase activity alternates with a protein disulfide...

    Polypeptides: Ecto-NOX disulfide-thiol exchanger 2
  5. Target

    Spectrin beta chain, non-erythrocytic 1

    go.drugbank.com/bio_entities/BE0004593
    TargetHumans

    Fodrin, which seems to be involved in secretion, interacts with calmodulin in a calcium-dependent manner and is thus candidate for the calcium-dependent movement of the cytoskeleton at the membrane. Plays a critical role in central nervo...

    Polypeptides: Spectrin beta chain, non-erythrocytic 1Synonyms: Spectrin, non-erythroid beta chain 1
  6. Drug

    Pafolacianine

    go.drugbank.com/drugs/DB15413
    ApprovedInvestigational

    It emits fluorescence within a range of 790 nm to 815 nm with a peak emission of 796 nm. … of 776 nm.

  7. Drug

    Ozenoxacin

    go.drugbank.com/drugs/DB12924
    Approved

    that has demonstrated safe and effective therapy in both the adult and pediatric population. … s Xepi (ozenoxacin 1%) as a topically applied cream indicated for the treatment of impetigo caused by *Staphylococccus aureus* or *Streptococcus pyogenes* in adult and pediatric patients 2 months of age

  8. Drug

    Artenimol

    go.drugbank.com/drugs/DB11638
    ApprovedInvestigational

    Artemisinin combination therapy is highly effective against malaria and stongly recommended by the World Health Organization [L1156]. … It was first authorized for market by the European Medicines Agency in October 2011 in combination with [DB13941] as the product Eurartesim.

  9. Drug

    DL-dimyristoylphosphatidylglycerol

    go.drugbank.com/drugs/DB11284
    Approved

    DL-dimyristoylphosphatidylglycerol is a phospholipid used in commercially available pharmaceutical preparations to solubilize drugs for injection.

  10. Drug

    Finerenone

    go.drugbank.com/drugs/DB16165
    ApprovedInvestigational

    Finerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart … [A236544,L34739] Finerenone was granted FDA approval on 9 July 2021,[L34739] followed by the EMA approval on 11 March 2022.[L41449]